Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Londos Elisabet) "

Sökning: WFRF:(Londos Elisabet)

Sortera/gruppera träfflistan
  • Ballard, Clive, et al. (författare)
  • alpha-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies
  • 2010
  • Ingår i: International Psychogeriatrics. - Cambridge University Press. - 1741-203X. ; 22:2, s. 321-327
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Dementia with Lewy bodies (DLB) accounts for 15-20%, of the millions of people worldwide with dementia. Accurate diagnosis is essential to avoid harm and optimize clinical management. There is therefore an urgent need to identify reliable biomarkers. Methods: Mass spectrometry was used to determine the specificity of antibody alpha-synuclein (211) for alpha-synuclein. Using gel electrophoresis we measured protein levels detected by alpha-synuclein specific antibodies in the cerebrospinal fluid (CSF) of DLB patients and compared them to age matched controls. Results: A 24 kDa band was detected using alpha-synuclein specific antibodies which was significantly reduced in the CSF of DLB patients compared to age matched controls (p < 0.05). Further analysis confirmed that even DLB patients with mild dementia showed significant reductions in this protein in comparison to controls. Conclusions: The current study emphasizes the necessity for further studies of CSF alpha-synuclein as a biomarker of DLB and extends our previous knowledge by establishing a potential relationship between alpha-synuclein and the severity of cognitive impairment. The identification of this 24 kDa protein is the next important step in these studies.
  • Brunnström, Hans, et al. (författare)
  • Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies.
  • 2013
  • Ingår i: International Journal of Geriatric Psychiatry. - John Wiley and Sons Ltd. - 1099-1166. ; 28:7, s. 738-744
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: The presence of concomitant Alzheimer pathology has been linked to earlier death in cases with dementia with Lewy bodies (DLB). Recently, elevated cerebrospinal fluid (CSF) tau protein levels have been reported to be associated with shorter survival in clinically diagnosed DLB. Correlations between CSF biomarkers and neuropathological findings in DLB are missing. The aim of this study was to investigate correlations between CSF biomarker levels and histopathological findings, with a focus on concomitant Alzheimer pathology, in neuropathologically verified DLB cases. METHODS: The extent of neurofibrillary pathology (Braak stage), neuritic plaques (CERAD stage), Alzheimer pathology (PPAD9 stage) and cerebral amyloid angiopathy was assessed in 16 cases with DLB in whom total tau (T-tau), hyperphosphorylated tau and amyloid beta 1-42 (Aβ42) protein levels in CSF had been analyzed in vivo. Demographic and clinical data were collected. RESULTS: Both Braak and PPAD9 stages were inversely correlated with Aβ42 levels, whereas CERAD stage showed no significant correlations. Cerebral amyloid angiopathy correlated positively with T-tau and T-tau/Aβ42 ratio, and inversely with Aβ42 levels, but the group showed a very heterogeneous extent of cerebral amyloid angiopathy. CONCLUSIONS: The burden of concomitant Alzheimer pathology correlates with CSF Aβ42 but not with T-tau levels in cases with neuropathologically defined DLB. Copyright © 2012 John Wiley & Sons, Ltd.
  • Buchhave, Peder, et al. (författare)
  • Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
  • 2009
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 4:7
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The CSF biomarkers tau and Abeta42 can identify patients with AD, even during the preclinical stages. However, previous studies on longitudinal changes of tau and Abeta42 in individual patients with AD and elderly controls report somewhat inconsistent results. METHODOLOGY/PRINCIPAL FINDINGS: We investigated the levels of tau and Abeta42 at baseline and after 1 year in 100 patients with AD. In a second cohort of 45 AD patients we measured the CSF biomarkers at baseline and after 2 years. Moreover, in 34 healthy elderly controls the CSF biomarkers were followed for 4 years. The baseline levels of tau were increased with >60% in AD patients compared to controls (p<0.001), while baseline Abeta42 levels were decreased with >50% (p<0.001). In the AD group followed for 2 years, tau increased with 16% compared to the baseline levels (p<0.05). However, the levels of tau were stable over 4 years in the controls. The levels of Abeta42 did not change significantly over time in any of the groups. In the patients with AD, tau was moderately associated with worse cognitive performance already at baseline (p<0.05). CONCLUSIONS/SIGNIFICANCE: Tau and Abeta42 in CSF seem to reflect the underlying disease state in both early and late stages of AD. The slight increase in tau over time observed in the patients with AD is modest when compared to the relatively large difference in absolute tau levels between AD patients and controls. Therefore, these markers maintain their usefulness as state markers over time and might serve as surrogate markers for treatment efficacy in clinical trials.
  • Creese, Byron, et al. (författare)
  • Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias
  • 2014
  • Ingår i: The American Journal of Geriatric Psychiatry. - Elsevier. - 1545-7214. ; 22:6, s. 580-586
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: To determine whether the 5HTTLPR serotonin transporter polymorphism is associated with delusions and hallucinations in people with dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD). Design: Prospective cohort study. Participants: A total of 187 individuals, recruited from centres in Norway, Sweden, and the United Kingdom were included in this study; 97 with clinically or neuropathologically diagnosed DLB/PDD and 90 cognitively normal individuals as a comparison group. Measurements: All participants with dementia underwent serial evaluation of neuropsychiatric symptoms to assess the presence of persistent delusions and hallucinations using the Columbia University Scale for Psychopathology in Alzheimer disease, the Neuropsychiatric Inventory, or the Present Behavioural Examination. Severity of cognitive impairment was measured using the Mini Mental State Examination (MMSE). Individuals were genotyped for the 5HTTLPR polymorphism. Results: Logistic regression demonstrated that homozygosity for the L/L genotype and lower MMSE were associated with an increased risk for delusions (odds ratio: 11.5 and 1.16, respectively). Neither was significantly associated with hallucinations. Conclusions: This study is the first to demonstrate the 5HTTLPR polymorphism is associated with delusions in Lewy body dementias, with important implications regarding the mechanisms underlying this symptom across the AD/DLB/PDD spectrum. Further studies are warranted to investigate this relationship further and examine treatment opportunities.
  • Creese, Byron, et al. (författare)
  • No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias
  • 2012
  • Ingår i: Neuroscience Letters. - Elsevier. - 0304-3940. ; 531:1, s. 1-4
  • Tidskriftsartikel (refereegranskat)abstract
    • We sought to determine whether the COMT val158met polymorphism (rs4680) is associated with delusions and hallucinations in people with dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A total of 218 individuals, recruited from centres in Norway, Sweden and the UK were included in this study; 121 with clinically or neuropathologically diagnosed DLB/PDD and 97 age-matched, cognitively normal controls. All participants with dementia underwent serial evaluation of neuropsychiatric symptoms to assess the presence of persistent delusions and hallucinations using the Columbia University Scale for Psychopathology in Alzheimer's disease, the Neuropsychiatric Inventory or the Present Behavioural Examination. Severity of cognitive impairment was measured using the Mini Mental State Examination (MMSE). Both controls and participants with dementia were genotyped for rs4680. In contrast to previous findings, analysis by logistic regression failed to find any associations between rs4680 and psychotic symptoms. Larger studies in well characterised cohorts are warranted in order to investigate this relationship further. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Johansson, C, et al. (författare)
  • Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.
  • 2011
  • Ingår i: International Journal of Geriatric Psychiatry. - John Wiley and Sons Ltd. - 1099-1166. ; 26, s. 206-213
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: This 30-week extension trial was a continuation of the first double-blind randomized controlled trial (RCT) to study memantine in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). The objective was to evaluate the presence of recurrence of symptoms upon drug withdrawal. Furthermore, the aim was to explore washout dynamics in order to inform clinical practice. METHODS: Patients were enrolled from psychiatric, memory and neurological outpatient clinics in Norway, Sweden and the UK. The trial comprised a 4-week washout period and a 26-week open-label treatment period. Outcome measures were presence of recurrence of symptom upon drug withdrawal, Clinical Global Impression of Change (CGIC) and modified motor Unified Parkinson's Disease Rating Scale (UPDRS). RESULTS: recurrence of symptoms occurred more frequently (p = 0.04) in patients receiving memantine (58%) than in patients receiving placebo (25%). There was a significant global deterioration (p = 0.0003) during washout within the memantine group as measured by CGIC. The patients seemed to recover during the open-label treatment, however these findings were non-significant. CONCLUSIONS: The findings inform clinical practice that any possible memantine-associated benefits might be rapidly lost after drug withdrawal. The magnitude of deterioration suggests a symptomatic rather than a disease-modifying effect of the drug. Open-label results should merely be considered inspiration for future trials. Copyright (c) 2010 John Wiley & Sons, Ltd.
  • Jones, Emma L., et al. (författare)
  • A Pilot Study Examining Associations between DYRK1A and alpha-Synuclein Dementias
  • 2012
  • Ingår i: Neurodegenerative Diseases. - Karger. - 1660-2862. ; 10:1-4, s. 229-231
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: DYRK1A is a kinase targeting several proteins associated with the pathology of dementias, including alpha-synuclein and amyloid precursor protein. It is not clear if DYRK1A genetics are associated with neurodegenerative conditions. Objective: To determine if DYRK1A also has a genetic association with alpha-synuclein dementias such as dementia with Lewy bodies and Parkinson's disease dementia. Methods: DNA samples from prospectively followed cohorts of control and dementia individuals were genotyped for the DYRK1A rs8126696 polymorphism. Results: The rs8126696 polymorphism altered the risk of developing an alpha-synuclein-associated dementia. Conclusion: DYRK1A could prove to be an important therapeutic target as it interacts with several proteins associated with the development of pathology in dementia. Copyright (C) 2012 S. Karger AG, Basel
  • Kramberger, Milica G., et al. (författare)
  • Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort
  • 2017
  • Ingår i: Journal of Alzheimer's Disease. - IOS Press. - 1387-2877. ; 57:3, s. 787-795
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Objective: The aim of this study was to describe the rate and clinical predictors of cognitive decline in dementia with Lewy bodies (DLB), and compare the findings with Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) patients. Methods: Longitudinal scores for the Mini-Mental State Examination (MMSE) in 1,290 patients (835 DLB, 198 PDD, and 257 AD) were available from 18 centers with up to three years longitudinal data. Linear mixed effects analyses with appropriate covariates were used to model MMSE decline over time. Several subgroup analyses were performed, defined by anti-dementia medication use, baseline MMSE score, and DLB core features. Results: The mean annual decline in MMSE score was 2.1 points in DLB, compared to 1.6 in AD (p=0.07 compared to DLB) and 1.8 in PDD (p=0.19). Rates of decline were significantly higher in DLB compared to AD and PDD when baseline MMSE score was included as a covariate, and when only those DLB patients with an abnormal dopamine transporter SPECT scan were included. Decline was not predicted by sex, baseline MMSE score, or presence of specific DLB core features. Conclusions: The average annual decline in MMSE score in DLB is approximately two points. Although in the overall analyses there were no differences in the rate of decline between the three neurodegenerative disorders, there were indications of a more rapid decline in DLB than in AD and PDD. Further studies are needed to understand the predictors and mechanisms of cognitive decline in DLB.
  • Larsson, Victoria, et al. (författare)
  • Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson's Disease Dementia.
  • 2011
  • Ingår i: Dementia and Geriatric Cognitive Disorders. - Karger. - 1420-8008. ; 32:4, s. 227-234
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias. Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer's disease (AD) in domains according to the WHO's classification of health. Results: Baseline QOL shows lower ratings for body functions over environmental factors in DLB/PDD. Treatment with memantine significantly improves life as a whole compared to placebo and improves total QOL, body function and structure. Conclusion: This study shows that memantine improves QOL in Lewy body dementias. We also demonstrate important QOL patterns which can be used in clinical practice. Copyright (C) 2011 S. Karger AG, Basel
Skapa referenser, mejla, bekava och länka
fritt online (65)
Typ av publikation
tidskriftsartikel (120)
konferensbidrag (18)
forskningsöversikt (2)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (128)
övrigt vetenskapligt (21)
Londos, Elisabet, (140)
Minthon, Lennart, (94)
Hansson, Oskar, (45)
Wattmo, Carina, (39)
Zetterberg, Henrik, (26)
Blennow, Kaj (25)
visa fler...
Londos, E (20)
Aarsland, D, (16)
Aarsland, Dag, (15)
Minthon, L (14)
Ballard, C (10)
Ballard, Clive (9)
Nägga, Katarina, (9)
Stomrud, Erik, (8)
Palmqvist, Sebastian (8)
Larsson, Victoria, (8)
Zetterberg, H (7)
Nielsen, Henrietta, (7)
Wallin, Åsa, (7)
Wennström, Malin, (7)
Blennow, K (6)
Boström, Fredrik, (6)
Bras, Jose (6)
Rosén, Ingmar, (5)
Zetterberg, Henrik, ... (5)
Lundh, Thomas (5)
Gustafson, Lars (5)
Passant, Ulla, (5)
Gerhardsson, Lars, (5)
Andreasson, Ulf, (5)
Guerreiro, Rita (5)
Blanc, Frédéric, (4)
Singleton, Andrew (4)
Nilsson, Christer, (4)
Parkkinen, Laura (4)
Al-Sarraj, Safa (4)
Revesz, Tamas (4)
van Westen, Danielle ... (4)
Ross, Owen A. (4)
Hansson, O (4)
Brun, Arne, (4)
Lees, Andrew (4)
Troakes, Claire (4)
Pastor, Pau (4)
Morgan, Kevin (4)
Lashley, Tammaryn (4)
Darwent, Lee (4)
Ansorge, Olaf (4)
Escott-Price, Valent ... (4)
Marder, Karen (4)
visa färre...
Lunds universitet (133)
Göteborgs universitet (40)
Karolinska Institutet (22)
Linköpings universitet (5)
Luleå tekniska universitet (1)
Engelska (137)
Svenska (3)
Danska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (140)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy